ClinicalTrials.Veeva

Menu
O

Orlando Clinical Research Center | Orlando, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

BMS-986177
Daclatasvir
BMS-650032
BMS-790052
Surufatinib
CIN-107
TD-4208
XNW4107
Tirzepatide
SSP-004184

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 247 total trials

A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)

Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (L...

Enrolling
Hepatic Impairment
Hepatic Insufficiency
Drug: Enlicitide

Evaluate simufilam levels in the blood of hepatically impaired individuals compared to Healthy individuals of similar demographics

Enrolling
Hepatic Insufficiency
Drug: Simufilam

The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic functi...

Enrolling
Liver Diseases
Drug: Etavopivat

The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relat...

Enrolling
Hepatic Impairment
Drug: Apalutamide

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemabrutinib (MK-1026) following a single oral dose of nemtabrutinib in p...

Enrolling
Hepatic Impairment (HI)
Drug: Nemtabrutinib

The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered t...

Not yet enrolling
Healthy
Hepatic Insufficiency
Drug: Olomorasib

The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in hea...

Enrolling
Hepatic Impairment
Healthy Volunteers
Drug: Repotrectinib

This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subj...

Not yet enrolling
COVID-19
Drug: ALG-097558

This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with severe renal impairment and subjects...

Begins enrollment this month
COVID 19
Drug: ALG-097558

The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal r...

Enrolling
Renal Impairment
Drug: VIR-2218

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD).CKD is a condition in which the kidneys' ability to wo...

Enrolling
Hepatic Impairment
Chronic Kidney Disease
Drug: BAY3283142

This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with n...

Enrolling
Hepatic Impairment
Drug: DZD9008

The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measur...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide

The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic...

Enrolling
Hepatic Impairment
Healthy Volunteers
Drug: BMS-986369

Trial sponsors

Bristol-Myers Squibb (BMS) logo
Lilly logo
Pfizer logo
Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo
Novartis logo
Janssen (J&J Innovative Medicine) logo
Bayer logo
Boehringer Ingelheim logo
Eisai logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems